CMMB Chemomab Therapeutics Ltd

Price (delayed)

$1.805

Market cap

$13.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.44

Enterprise value

$5.94M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 11

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of ...

Highlights
The debt has shrunk by 100% YoY
CMMB's EPS has surged by 54% year-on-year and by 45% since the previous quarter
CMMB's quick ratio has soared by 82% YoY but it is down by 13% from the previous quarter
CMMB's equity is up by 10% from the previous quarter but it is down by 9% YoY

Key stats

What are the main financial stats of CMMB

CMMB stock price

How has the Chemomab Therapeutics stock price performed over time
Intraday
4.94%
1 week
-12.8%
1 month
11.42%
1 year
-66.45%
YTD
9.39%
QTD
14.97%

Financial performance

How have Chemomab Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.57M
Net income
-$9M
Gross margin
N/A
Net margin
N/A
CMMB's net income is up by 35% year-on-year and by 11% since the previous quarter
Chemomab Therapeutics's operating income has increased by 35% YoY and by 11% from the previous quarter

Price vs fundamentals

How does CMMB's price correlate with its fundamentals

Growth

What is Chemomab Therapeutics's growth rate over time

Valuation

What is Chemomab Therapeutics stock price valuation
P/E
N/A
P/B
0.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CMMB's EPS has surged by 54% year-on-year and by 45% since the previous quarter
CMMB's price to book (P/B) is 44% less than its last 4 quarters average of 1.6 and 32% less than its 5-year quarterly average of 1.3
CMMB's equity is up by 10% from the previous quarter but it is down by 9% YoY

Efficiency

How efficient is Chemomab Therapeutics business performance
Chemomab Therapeutics's return on invested capital has decreased by 38% YoY and by 7% QoQ
CMMB's return on equity is up by 21% year-on-year and by 8% since the previous quarter
The return on assets has increased by 9% year-on-year and by 5% since the previous quarter

Dividends

What is CMMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMMB.

Financial health

How did Chemomab Therapeutics financials performed over time
Chemomab Therapeutics's current ratio has surged by 82% YoY but it has decreased by 13% QoQ
CMMB's quick ratio has soared by 82% YoY but it is down by 13% from the previous quarter
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
CMMB's debt to equity has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.